| Name | Leucettine L41 |
| Description | Leucettine L41 (LeucettineL41) is a selective DYRK1A inhibitor that inhibits DYRK2, CLK1, and CLK3, inducing autophagy linked to CLK inhibition. It is used to study Alzheimer's disease and memory deficits. |
| In vitro | Leucettine L41 is a potent inhibitor of bispecic tyrosine phosphorylated regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 with IC50 of 0.04, 0.035, 0.015, and 4.5 µM, respectively.
Leucettine L41 inhibits phosphorylation of serine/arginine-rich protein (SRp). [1] |
| In vivo | Leucettine L41(0.4, 1.2, 4 μg) prevented Aβ25-35-induced hippocampal memory impairment and neurotoxicity in mice. [2]
Leucettine L41(20 mg/kg, peritoneal injection) AAV-AD rat model showed decreased soluble P-tau form but unchanged soluble Aβ42 level. [4] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (10.74 mM), Sonication is recommended. DMSO : 80 mg/mL (260.33 mM), Sonication is recommended.
|
| Keywords | Leucettine-L41 | Leucettine L-41 | Leucettine L41 |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | 2,4,6-Trihydroxybenzoic acid | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Seliciclib | Dinaciclib |
| Related Compound Libraries | Bioactive Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | High-Efficiency Gene Editing Small Molecule Library |